Transgene Announces Upcoming Investor Meetings
14 Setembro 2023 - 12:45PM
Business Wire
Regulatory News:
TRANSGENE (Paris: TNG), a biotech company that designs
and develops virus-based immunotherapies for the treatment of
cancer, today announces that Management will participate in several
investor events, as set out below.
- Cantor Global Healthcare Conference, New York, USA:
September 26, 2023
- Investor Access Forum, Paris, France: October 9,
2023
- HealthTech Innovation Days 2023, Paris, France: October
24 & 25, 2023
Next scheduled financial communication
First Half 2023 Financial Results September 20,
2023, after trading hours – The company will host a conference call
at 6:00 pm CET
***
About Transgene Transgene (Euronext: TNG) is a
biotechnology company focused on designing and developing targeted
immunotherapies for the treatment of cancer. Transgene’s programs
utilize viral vector technology with the goal of indirectly or
directly killing cancer cells. The Company’s clinical-stage
programs consist of a portfolio of therapeutic vaccines and
oncolytic viruses: TG4050, the first individualized therapeutic
vaccine based on the myvac® platform, TG4001 for the treatment of
HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three
oncolytic viruses based on the Invir.IO® viral backbone. With
Transgene’s myvac® platform, therapeutic vaccination enters the
field of precision medicine with a novel immunotherapy that is
fully tailored to each individual. The myvac® approach allows the
generation of a virus-based immunotherapy that encodes
patient-specific mutations identified and selected by Artificial
Intelligence capabilities provided by its partner NEC. With its
proprietary platform Invir.IO®, Transgene is building on its viral
vector engineering expertise to design a new generation of
multifunctional oncolytic viruses. Additional information about
Transgene is available at: www.transgene.fr Follow us on Twitter:
@TransgeneSA
Disclaimer This press release contains forward-looking
statements, which are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those
anticipated. The occurrence of any of these risks could have a
significant negative outcome for the Company’s activities,
perspectives, financial situation, results, regulatory authorities’
agreement with development phases, and development. The Company’s
ability to commercialize its products depends on but is not limited
to the following factors: positive pre-clinical data may not be
predictive of human clinical results, the success of clinical
studies, the ability to obtain financing and/or partnerships for
product manufacturing, development and commercialization, and
marketing approval by government regulatory authorities. For a
discussion of risks and uncertainties which could cause the
Company’s actual results, financial condition, performance or
achievements to differ from those contained in the forward-looking
statements, please refer to the Risk Factors (“Facteurs de Risque”)
section of the Universal Registration Document, available on the
AMF website (http://www.amf-france.org) or on Transgene’s website
(www.transgene.fr). Forward-looking statements speak only as of the
date on which they are made, and Transgene undertakes no obligation
to update these forward-looking statements, even if new information
becomes available in the future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230914452172/en/
Transgene: Lucie Larguier Director Corporate
Communications & IR +33 (0)3 88 27 91 04
investorrelations@transgene.fr
Media: MEDiSTRAVA Consulting Frazer /Sylvie
Berrebi +44 (0)203 928 6900 transgene@medistrava.com
Transgene (EU:TNG)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Transgene (EU:TNG)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024